Company intelligence / Profile preview

Beckley Psytech

Oxford, Oxfordshire, United Kingdombeckleypsytech.com ↗
Ownership
Private
Development stage
Phase 2
01

Overview

Beckley Psytech has completed enrollment in a global Phase IIb study of BPL-003, their proprietary intranasal formulation of synthetic 5-MeO-DMT for Treatment Resistant Depression. Initial Phase IIa data showed rapid onset and durable antidepressant effects from a single dose with good tolerability. Topline results from the ongoing Phase IIb trial are expected mid to late 2025. Their second candidate ELE-101, an intravenous formulation of psilocin targeting Major Depressive Disorder, is in early clinical stages with initial results anticipated in the first half of 2024[3][5][6][7][9].

Therapeutic areas
Psychiatry
Modalities
Short-duration psychedelic compounds, including synthetic formulations of 5-MeO-DMT and psilocin administered intranasally or intravenouslyRapid acting psychedelic-based medicines designed for mental health conditions
Industry
Biotech
02

Drug pipeline

4 assets

psilocin benzoate

2

3 more assets in the full pipeline.

Request access →
03

Partnerships

Strategic investment and collaboration with atai Life Sciences since January 2024. atai holds a significant ownership stake (~35.5%) and collaborates on digital therapeutics development, commercialization planning, and market access activities[3][6][7].

Beyond the preview

Go deeper on Beckley Psytech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beckley Psytech.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call